Drug Combo Marks Advance Against Bladder Cancer
MONDAY, March 11, 2024 (HealthDay News) — A cancer drug duo more than doubled the survival of people battling the most common form of advanced bladder cancer, trial results show. Patients who took a combo of meds called EV+P — enfortumab vedotin and pembrolizumab (Keytruda) — had an average 31.5Continue Reading